ASTRO: DCE-MRI predicts spine tumor recurrence
Article Thumbnail ImageOctober 30, 2012 -- BOSTON - By measuring plasma volume in spine tumors with dynamic contrast-enhanced (DCE) MRI, physicians can better assess treatment response even when conventional MRI results show little regression after successful radiosurgery, according to a study presented on Monday at the American Society for Radiation Oncology (ASTRO) meeting.

To get access to this article and all of the content on AuntMinnie.com, create a free account or sign-in now.

Member Sign In:
  MemberID or E-mail Address:
  Password:
(?)

New AuntMinnie.com Members

Becoming a Member is FREE!

  • Real-time radiology-specific news
  • Case of the Day and Teaching Files
  • Focused topics digital communities
  • Lively, discussion groups
  • Medical imaging bookstore
  • SalaryScan
  • Job Boards
  • Online CME
  • Bookstore, market reports, more …
  • Conference Calendar
  • User-controlled eNewsletters
  • … registration is FREE and easy!
  • The researchers from Memorial Sloan-Kettering Cancer Center in New York City also concluded that plasma volume was the only significant variable that could accurately predict local recurrence or control of a lesion in the spine.

    "This is clinically relevant because we now have tools that not only look at the actual anatomy or size of the lesion inside the spine, but also look at what is going on inside the tumor after high-dose radiation," said lead study author Dr. Yoshiya Yamada from the center's department of radiation oncology.

    The study evaluated 19 patients who received both pre- and post-treatment contrast-enhanced MRI scans. Images were acquired on a 1.5-tesla MRI system (GE Healthcare) with an eight-channel spine coil. At least two follow-up MRI scans were performed on all 19 individuals at a median time of 17 months, ranging from eight to 48 months.

    Fourteen of the 19 patients received a standard dose of 2,400 cGy during stereotactic radiosurgery. Seventeen individuals were later found to have locally controlled tumors, while two patients experienced local tumor recurrence.

    For the purposes of this study, Yamada and colleagues determined poor treatment results through radiographic evidence of tumor progression on MR angiography, CT, or PET/CT imaging.

    In their analysis of contrast-enhanced MR images, the researchers found that a mean plasma volume reduction of 66% in tumors was associated with control of spine tumor growth after treatment. The blood-flow decrease in tumors ranged from 21% to 99%.

    By comparison, plasma volume increased from a low of 145% to a high of 207% in cases of recurring tumors.

    Based on the results, Yamada and colleagues concluded that plasma volume was significantly associated with tumor response. In addition, DCE-MRI can suggest treatment response even when conventional MRI studies demonstrate minimal or no regression after successful spine stereotactic radiotherapy, they noted.

    Yamada said that this study is the first clinical experience to confirm their work in preclinical animal models. Additional research must be done to confirm these findings among a larger patient population, he added.

    Study disclosures

    Among Yamada's affiliations, he has served as a consultant for Varian Medical Systems.

    || About || Advertising || AuntMinnieCME.com || Bookstore || Breast MRI || Career Center || Case of the Day || Communities || Conferences || Contact Us || ECR News 2014 || Education || Equipment Classifieds || Europe || Facebook || Forums || Home || Links || Marketplace || Middle East || Mobile || Molecular Breast Imaging || New Installations || News in Brief || People in the News || Privacy Policy || RSNA News 2013 || Reference || Salary Survey Results || Trends in Radiology || Twitter || Vendor Connect || Webinars || XML/RSS ||

    Copyright © 2014 AuntMinnie.com. All Rights Reserved.